Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 674, Issue 2-3, Pages 391-396Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2011.08.029
Keywords
Acute lung injury; Lipopolysaccharide; Crocetin; Cytokine; NF-kappa b; Inflammation
Categories
Ask authors/readers for more resources
Crocetin, a carotenoid compound, has been shown to reduce expression of inflammation and inhibit the production of reactive oxygen species. In the present study, the effect of crocetin on acute lung injury induced by lipopolysaccharide (LPS) was investigated in vivo. In the mouse model, pretreatment with crocetin at dosages of 50 and 100 mg/kg reduced the LPS-induced lung oedema and histological changes, increased LPS-impaired superoxide dismutase (SOD) activity, and decreased lung myeloperoxidase (MPO) activity. Furthermore, treatment with crocetin significantly attenuated LPS-induced mRNA and the protein expressions of interleukin-6 (IL-6), macrophage chemoattractant protein-1 (MCP-1), and tumour necrosis factor-alpha (TNF-alpha) in lung tissue. In addition, crocetin at different dosages reduced phospho-I kappa B expression and NF-kappa B activity in LPS-induced lung tissue alteration. These results indicate that crocetin can provide protection against LPS-induced acute lung injury in mice. (C) 2011 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available